Brief: Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results
09/01/2026 13:39
Jan 9 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUES AND UPCOMING MILESTONES RHYTHM PHARMACEUTICALS INC - MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY RHYTHM PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EXPECTED Q1 2026 RHYTHM PHARMACEUTICALS INC - FY 2025 PRELIM PRODUCT REVENUES ABOUT $194 MILLION, UP 50% FROM FY2024 RHYTHM PHARMACEUTICALS INC - PRELIM Q4 2025 IMCIVREE REVENUES ABOUT $57 MILLION, UP 11% FROM Q3 Source text: ID:nGNX5s2TCj Further company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand